FOR BIOLOGIC-NAIVE PATIENTS WITH ANKYLOSING SPONDYLITIS
ASAS40 results in as fast as 16 weeks and maintained through week 521,2,4,5
COAST-V was not designed to test the noninferiority or superiority of Taltz to Humira
Among biologic-naive patients, 64% receiving Taltz, 59% receiving Humira, and 40% receiving placebo achieved ASAS20 at week 16. At week 52, 65% of patients receiving Taltz achieved ASAS20.
COAST-V was not designed to test the noninferiority or superiority of Taltz to Humira. Thus, these data should not be used to compare the efficacy between these products.
Additional week 52 results from COAST-W trial, NRI1, 3, 6
In COAST-W (TNFi-experienced) (Taltz 80 mg every 4 weeks n=114; placebo n=104), 34% of patients receiving Taltz achieved ASAS40 and 53% of patients receiving Taltz achieved ASAS20 at week 52.
SELECT IMPORTANT SAFETY INFORMATION
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.